A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 400

Sponsor: Eli Lilly and Company

Location: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa Chandler Arizona

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Eligibility Criteria

Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm) * Have a history of acute or chronic pancreatitis * All concomitant medications should be at a stable dose for at least 3 months prior to screening

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07589608). StuddyBuddy aggregates publicly available trial information.